As expected, S63845 displayed impressive potency at low nanomolar concentrations in preclinical in vitro and in vivo models of hematological malignancies, including MM, AML, CML and c-MYC-driven Burkitt lymphoma. This evidence concerns the gene MYC and Burkitt lymphoma.